NS-229 is an investigational selective Janus kinase 1 (JAK1) inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell activation. A global, randomized, double-blind ...

The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.